Streetbeat News

FBLG

FibroBiologics Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

1.25

Mkt cap

39M

Volume

285K

High

1.25

P/E Ratio

-2.05

52-wk high

14.70

Low

1.11

Div yield

N/A

52-wk low

1.06

FibroBiologics, Inc. (Nasdaq: FBLG) will host an in-person analyst day on February 12, 2025, to provide updates on their research and development strategy for fibroblast-based therapeutics targeting chronic diseases.

Portfolio Pulse from

February 05, 2025 | 2:30 pm

FibroBiologics, Inc. (Nasdaq: FBLG) has closed the second $5 million tranche of a $25 million financing agreement with Yorkville Advisors. This agreement allows FibroBiologics to sell up to $25 million of its common stock over two years.

Portfolio Pulse from

December 30, 2024 | 9:45 pm

FibroBiologics, Inc. (Nasdaq: FBLG) has entered into a Standby Equity Purchase Agreement with Yorkville Advisors, allowing it to sell up to $25 million of its common stock over two years. D. Boral Capital served as the exclusive placement agent for this financing.

Portfolio Pulse from

December 30, 2024 | 7:30 pm

FibroBiologics, Inc. has secured a $25 million financing agreement with Yorkville Advisors, allowing the company to sell up to $25 million of its common stock over two years. This financing will support its development of therapeutics for chronic diseases.

Portfolio Pulse from

December 23, 2024 | 1:00 pm

FibroBiologics, Inc. has filed a patent application for a cell-based therapeutic method to treat splenomegaly, expanding its portfolio of over 160 patents. This development highlights the company's focus on fibroblast-based treatments for chronic diseases.

Portfolio Pulse from

November 19, 2024 | 2:30 pm

FibroBiologics, Inc. has filed a patent application for methods using fibroblasts to reduce blood clots associated with IBMIR in cell-based therapies. This development could enhance the company's therapeutic offerings.

Portfolio Pulse from

November 14, 2024 | 2:30 pm

FibroBiologics has reported its third quarter 2024 financial results and provided a corporate update. The company is preparing for a Phase 1/2 clinical trial in Australia for its fibroblast-based spheroids product candidate, CYWC628, aimed at treating diabetic foot ulcers, with plans to start in Q2 2025.

Portfolio Pulse from

November 12, 2024 | 9:30 pm

Wall Street analysts have initiated coverage on several companies with a bullish outlook. NANO Nuclear Energy, FibroBiologics, Invivyd, and Carisma Therapeutics received Buy ratings with significant price targets, indicating potential upside.

Portfolio Pulse from Avi Kapoor

October 30, 2024 | 4:05 pm

HC Wainwright & Co. has initiated coverage on FibroBiologics with a Buy rating and set a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:45 pm

FibroBiologics has announced successful results for its Artificial Thymus Organoid, which demonstrated over 50 days of functionality post-transplant and the production of diverse, mature T cells. This development could have significant implications for the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 1:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.